Literature DB >> 2421934

A radioimmunoassay procedure for tallysomycin S10b in human plasma and urine.

R C Gaver, C W Dixon, R D Smyth.   

Abstract

A simple and sensitive radioimmunoassay (RIA) procedure was developed and validated for the analysis of tallysomycin S10b in human plasma and urine. The assay utilized antisera developed in rabbits, 125I-tallysomycin as the radioligand, and dextran-coated charcoal to separate free and bound antigen. The antibody was specific in that it did not cross-react with either tallysomycin A or bleomycin. The lower limit of quantification was 5 ng per ml plasma or urine, and the linear range of the assay was 5-320 ng tallysomycin S10b base per ml plasma or urine. The within-day assay variability (%RSD) for plasma and urine was 11% at a concentration of 50 ng per ml, and 3% and 7% for plasma and urine, respectively at 200 ng per ml. Within-day accuracy ranged from 100% to 108% of the theoretical value. Tallysomycin S10b was stable in human plasma and urine at concentrations of 20 and 160 ng per ml for at least 7 months when stored at -20 degrees C. The method was applied to the analysis of plasma and urine samples from a patient given tallysomycin S10b as part of a phase I study.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2421934     DOI: 10.1007/bf00293979

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  7 in total

1.  Preparation of iodine-131 labelled human growth hormone of high specific activity.

Authors:  W M HUNTER; F C GREENWOOD
Journal:  Nature       Date:  1962-05-05       Impact factor: 49.962

2.  A radioimmunoassay for tallysomycin.

Authors:  A Broughton; J E Strong; S T Crooke; A W Prestayko; J Knight
Journal:  Cancer Treat Rep       Date:  1979 Nov-Dec

3.  Radioimmunoassay of bleomycin.

Authors:  A Broughton; J E Strong
Journal:  Cancer Res       Date:  1976-04       Impact factor: 12.701

4.  Tallysomycin, a new antitumor antibiotic complex related to bleomycin. V. Production, characterization and antitumor activity of tallysomycin S10b, a new biosynthetic tallysomycin derivative.

Authors:  T Miyaki; K Numata; Y Nishiyama; O Tenmyo; M Hatori; H Imanishi; M Konishi; H Kawaguchi
Journal:  J Antibiot (Tokyo)       Date:  1981-06       Impact factor: 2.649

5.  Tallysomycin, a new antitumor antibiotic complex related to bleomycin. IV. New biosynthetic derivatives of tallysomycin.

Authors:  T Miyaki; O Tenmyo; K Numata; K Matsumoto; H Yamamoto; Y Nishiyama; M Ohbayashi; H Imanishi; M Konishi; H Kawaguchi
Journal:  J Antibiot (Tokyo)       Date:  1981-06       Impact factor: 2.649

6.  The toxicological evaluation of tallysomycin s10b--biosynthetic tallysomycin derivative.

Authors:  R A Buroker; C R Comereski; D Barnett; R S Hirth; H Madissoo; G H Hottendorf
Journal:  Drug Chem Toxicol       Date:  1984       Impact factor: 3.356

7.  Tallysomycin S10b: experimental antitumor activity and toxicity.

Authors:  J E Schurig; W C Rose; R S Hirth; A Schlein; J B Huftalen; A P Florczyk; W T Bradner
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

  7 in total
  2 in total

1.  Tallysomycin S10b--a phase I trial.

Authors:  P G Sørensen; H Pedersen; H V Clausen; H H Hansen
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

2.  Phase I trial of tallysomycin S10b, a bleomycin analogue.

Authors:  F P Paolozzi; R C Gaver; N B Newman; B J Poiesz; S DeFino; A Louie; R L Comis
Journal:  Invest New Drugs       Date:  1990-05       Impact factor: 3.850

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.